Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study
![Thumbnail](/xmlui/bitstream/handle/10234/190415/lizan_2020_treat.pdf.jpg?sequence=5&isAllowed=y)
Visualitza/
Impacte
![Google Scholar](/xmlui/themes/Mirage2/images/uji/logo_google.png)
![Microsoft Academico](/xmlui/themes/Mirage2/images/uji/logo_microsoft.png)
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC studyAutoria
Data de publicació
2019-04-03Editor
Elsevier; Elsevier [Commercial Publisher] International Society of Geriatric Oncology (SIOG)ISSN
1879-4068Cita bibliogràfica
BOQUÉ, Concepción, et al. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study. Journal of Geriatric Oncology, 2020, vol. 11, no 1, p. 24-30.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.geriatriconcology.net/Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Objective: To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse ... [+]
Objective: To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse,
condition that mainly afflicts older adults.
Methods: A discrete choice experiment (DCE) was conducted among haematologists and hospital pharmacists. A
literature review and a focus group informed the DCE design. CLL treatment settings were defined by seven attributes: four patient/disease-related attributes (age, functional status, comorbidities, and risk of the disease)
and three treatment-related attributes (efficacy [hazard ratio of progression-free survival, HR-PFS], rate of
discontinuations due to adverse events and cost). A mixed-logit model was used to determine choice-based preferences. Relative importance (RI) of attributes was calculated and compared between stakeholders. Willingnessto-pay (WTP) was estimated through the DCE. Besides, nine ad-hoc questions were posed, to explore more in
depth CLL treatment decision making.
Results: A total of 130 participants (72 haematologists and 58 hospital pharmacists) answered the DCE. All attributes were significant predictors of preferences (p b 0.05) in the multinomial model. Higher RI was obtained for
treatment-related attributes: the highest rated being ‘cost’ (23.8%) followed by ‘efficacy’ (20.9%). Regarding
patient-related attributes, the highest RI was obtained for ‘age’ (18.1%). No significant differences (p N 0.05) in
RI between haematologists and pharmacists were found. WTP for the treatment was higher for younger CLL
patients. Ad-hoc questions showed that patient age and functional status influence treatment decisions.
Conclusions: For healthcare professionals, ‘cost’ and ‘efficacy’ (treatment-related attributes) and age (patientrelated attribute) are the ma [-]
Publicat a
Journal of Geriatric Oncology 11 (2020) 24–30Drets d'accés
© 2019 The Authors. Published by Elsevier Ltd.
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- MED_Articles [660]
Els següents fitxers sobre la llicència estan associats a aquest element: